业界动态监管公开信息 · FDA
FDA授予pirtobrutinib加速批准用于复发或难治性套细胞淋巴瘤
FDA Drugs · 2026-11-10 05:58
摘要
FDA授予pirtobrutinib加速批准用于复发或难治性套细胞淋巴瘤
English
FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma
FDA grants accelerated approval to pirtobrutinib for relapsed or refractory mantle cell lymphoma